

GREAT GRAY COLLECTIVE INVESTMENT TRUST

LAZARD US EQUITY CONCENTRATED CIT

FINANCIAL STATEMENTS

DECEMBER 31, 2024

WITH

REPORT OF INDEPENDENT AUDITORS

LAZARD US EQUITY CONCENTRATED CIT

TABLE OF CONTENTS

Report of Independent Auditors	1
Schedule of Investments	3
Statement of Assets and Liabilities	5
Statement of Operations	5
Statement of Changes in Net Assets	6
Financial Highlights	7
Notes to the Financial Statements	8



Report of Independent Auditors

To the Board of Managers of Great Gray Trust Company, LLC

Opinion

We have audited the accompanying financial statements of Lazard US Equity Concentrated CIT (the "Fund"), which comprise the statement of assets and liabilities, including the schedule of investments, as of December 31, 2024, and the related statements of operations and of changes in net assets for the year then ended, including the related notes, and the financial highlights for each of the periods indicated therein (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as of December 31, 2024, and the results of its operations and changes in its net assets for the year then ended and the financial highlights for each of the periods indicated therein, in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Fund and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Fund's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.



In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Fund's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Price waterhouse Coopers LLP

San Francisco, California April 30, 2025

Lazard US Equity Concentrated CIT

Schedule of Investments December 31, 2024

Common Stocks - 96,1% Communications - 3.5% Common Stocks - 96,1% DigitalBridge Group, Inc. 582,432 \$ 8,814,543 \$ 6,569,833 Consumer Discretionary - 18,0% 8,814,543 \$ 6,569,833 Amazon.com, Inc. 84,993 14,777,116 18,646,614 First Watch Restaurant Group, Inc. 36,11,84 6,600,047 6,535,534 Thor Industries, Inc. 91,502 9,262,257 30,837,420 33,939,805 Financials - 21,6% Charles Schwab Corporation/The 100,535 11,964,412 13,361,395 Corpsy, Inc. 21,021 6,290,280 7,113,927 First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 78,518 10,852,190 11,699,967 37,900,686 40,736,313 Health Care - 14.7% Axanor, Inc. 242,475 5,812,801 5,108,948 Axanor, Inc. 39,840 5,531,455 7,886,837 Vaxotyr, Inc. 39,840 5,531,455 7,886,837 30,094,777 27,575,093 Industrials 9.0% 30,094,777 27,		Principal Amount or Shares	Cost	Fair Value
Communications - 3.5% 582,432 \$ 8.814,543 \$ 6,569,833 Total Communications 582,432 \$ 8.814,543 \$ 6,569,833 Consumer Discretionary - 18.0% Amazon.com, Inc. 84,993 14,777,116 18,646,614 First Watch Restaurant Group, Inc. 351,184 6,808,047 6,535,534 Thor Industries, Inc. 91,502 9.252,257 8,757,657 Total Consumer Discretionary 91,502 9.252,257 8,757,657 Financials - 21.6% Charles Schwab Corporation/The 180,535 11,964,412 13,361,395 Corpay, Inc. 180,535 11,964,412 13,361,395 11,899,967 Total Financials - 21.6% 11,964,412 13,361,395 11,969,411 13,361,395 Corpay, Inc. 180,535 11,964,412 13,361,395 11,899,967 Total Financials Corporation/The 180,535 11,964,412 13,361,395 Cotal Financials 21,021 6,290,280 7,113,827 Total Health Care - 14.7% 4,870,585 7,886,837 37,900,686 40,736,313 Heatth	Common Stocks - 96.1%			
DigitalBridge Group, Inc. 582,432 \$ 8,814,543 \$ 6,569,833 Total Communications 6,8993 14,777,116 18,646,614 First Watch Restaurant Group, Inc. 84,993 14,777,116 18,646,614 First Watch Restaurant Group, Inc. 351,184 6,808,047 6,535,534 Thor Industries, Inc. 91,502 9,252,257 8,757,657 Total Consumer Discretionary 20,028,07,713,927 30,837,420 33,3939,805 Financials - 21.6% Charles Schwab Corporation/The 180,535 11,964,412 13,361,395 Corpay, Inc. 21,021 6,290,280 7,113,927 First American Financial Corporation 11,699,467 10,852,190 11,699,467 Total Financials 21,021 6,290,280 7,113,927 Total Financials 37,900,686 40,736,313 Health Care - 14.7% Xavontr, Inc. 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 29,802 7,513,935 7,886,837 Vaxcyte, Inc. 39,840 6,514,455 6,491,131 Total Health Care 51,066 </td <td></td> <td></td> <td></td> <td></td>				
Total Communications 8,814,543 6,569,833 Consumer Discretionary - 18.0% Amazon.com, Inc. 84,993 14,777,116 18,646,614 First Watch Restaurant Group, Inc. 351,184 6,808,047 6,535,534 Total Consumer Discretionary 91,502 9,252,257 8,757,657 Total Consumer Discretionary 30,837,420 33,393,805 Financials - 21.6% Charles Schwab Corporation/The 180,535 11,964,412 13,361,395 Corpay, Inc. 21,021 6,290,280 7,113,927 First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 76,518 11,669,967 11,669,967 11,669,967 37,900,686 40,736,313 Health Care - 14.7% Axamore Therapeutics, Inc. 93,214 8,570,585 7,886,837 Vaxcyte, Inc. 98,640 531,554 6,491,131 Total Industrials 9,036,912 7,575,093 11,094,1132 3,789,062 27,762,693 7,971,254 Total Industrials 51,056 7,558,198 9,036,912 7,502,931 <		582,432	\$ 8,814,543	\$ 6,569,833
Amazon.com, Inc. 84,993 14,777,116 18,646,614 First Watch Restaurant Group, Inc. 351,184 6,808,047 6,535,534 Thor Industries, Inc. 91,502 9,252,257 8,757,657 Total Consumer Discretionary 30,837,420 33,939,805 Financials - 21.6% 11,964,412 13,361,395 Charles Schwab Corporation/The 21,021 6,290,280 7,113,927 First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 78,518 11,964,412 13,361,395 Total Financials 11,964,412 13,361,395 11,964,412 13,361,395 Health Care - 14.7% 21,021 6,290,280 7,113,927 11,159,99,67 37,900,686 40,736,313 Health Care - 14.7% 242,475 5,812,801 5,108,948 37,900,686 40,736,313 Yeaxotry, Inc. 29,214 8,570,585 7,868,837 30,94,777 27,575,093 Industrials - 9.0% 90,805 9,179,936 8,088,177 27,558,198 9,036,912				
First Watch Restaurant Group, Inc. 351,184 6,808,047 6,335,534 Thor Industries, Inc. 91,502 9,252,257 8,757,657 Total Consumer Discretionary 30,837,420 33,939,805 Financials - 21.6% 11,964,412 13,361,395 Charles Schwab Corporation/The 21,021 6,290,280 7,113,827 First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 78,518 10,852,190 11,999,967 Total Financials 37,900,686 40,736,313 Health Care - 14.7% 39,214 8,570,585 7,886,837 Avantor, Inc. 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 93,214 8,570,585 7,886,837 Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials 9,036,912 7,762,693 7,971,254 Total Health Care 11,369	Consumer Discretionary - 18.0%			
Thor Industries, Inc. 91,502 9,252,257 8,757,657 Total Consumer Discretionary 30,837,420 33,939,805 Financials - 21.6% 11,964,412 13,361,395 Charles Schwab Corporation/The 180,535 11,964,412 13,361,395 Corpay, Inc. 21,021 6,290,280 7,113,927 First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 78,518 10,6852,190 11,699,967 Total Financials 7,900,686 40,736,313 Health Care - 14.7% 40,736,518 10,852,190 5,108,948 Axanor, Inc. 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 93,214 8,570,585 7,886,837 Vaxoyte, Inc. 98,805 9,179,936 8,088,177 Zotis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 27,952 7,971,254 13,0094,777 Industrials 27,558,198 9,036,912 7,752,639 7,971,254 15,320,891 17,008,166	Amazon.com, Inc.	84,993	14,777,116	18,646,614
Total Consumer Discretionary 30,837,420 33,939,805 Financials - 21.6% 11,964,412 13,361,395 Charles Schwab Corporation/The 180,535 11,964,412 13,361,395 Corpay, Inc. 21,021 6,290,280 7,113,927 First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 78,518 10,852,190 11,699,967 Total Financials 37,900,686 40,736,313 Health Care - 14.7% 40,852,190 11,699,967 Avantor, Inc. 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 93,214 8,570,585 7,866,837 Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 93,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials 10,303,094,777 27,575,093 Industrials 15,320,891 17,008,166 Total Health Care	First Watch Restaurant Group, Inc.	351,184	6,808,047	6,535,534
Financials - 21.6% 180,535 11,964,412 13,361,395 Corpay, Inc. 21,021 6,290,280 7,113,927 First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 78,518 10,852,190 11,699,967 Total Financials 78,518 10,852,190 11,699,967 Avantor, Inc. 78,518 10,852,190 11,699,967 Avantor, Inc. 93,214 8,700,885 7,868,837 Axsome Therapeutics, Inc. 93,214 8,700,885 7,868,837 Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9,0% 51,056 7,558,198 9,036,912 Boeing Co/The 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 15,320,891 17,008,166 Technology - 29,3% Atvanced Micro Devices, Inc. 31,369 4,401,432	Thor Industries, Inc.	91,502	9,252,257	8,757,657
Charles Schwab Corporation/The 180,535 11,964,412 13,361,395 Corpay, Inc. 21,021 6,290,280 7,113,927 First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 78,518 10,852,190 11,699,967 Total Financials 37,900,686 40,736,313 Health Care - 14.7% 39,214 8,570,585 7,868,837 Avantor, Inc. 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 99,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 30,094,777 27,575,093 Boeing Co./The 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 11,300,314,50 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc.	Total Consumer Discretionary		30,837,420	33,939,805
Corpay, Inc. 21,021 6,290,280 7,113,927 First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 78,518 10,852,190 11,699,967 Total Financials 37,900,686 40,736,313 Health Care - 14.7% 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 93,214 8,570,585 7,866,837 Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 51,056 7,558,198 9,036,912 Boeing Co./The 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 15,320,891 17,008,166 Technology - 29.3% Advanced Micro Devices, Inc. 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 </td <td>Financials - 21.6%</td> <td></td> <td></td> <td></td>	Financials - 21.6%			
First American Financial Corporation 137,108 8,793,804 8,561,024 Intercontinental Exchange, Inc. 78,518 10,852,190 11,699,967 Total Financials 37,900,686 40,736,313 Health Care - 14.7% 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 93,214 8,570,585 7,886,837 Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 51,056 7,558,198 9,036,912 Boeing Co./The 51,056 7,558,198 9,036,912 Total Industrials 9.0% 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 404,401,432 3,789,062 Advanced Micro Devices, Inc. 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 <td>Charles Schwab Corporation/The</td> <td>180,535</td> <td>11,964,412</td> <td>13,361,395</td>	Charles Schwab Corporation/The	180,535	11,964,412	13,361,395
Intercontinental Exchange, Inc. 78,518 10,852,190 11,699,967 Total Financials 37,900,686 40,736,313 Health Care - 14.7% 4vantor, Inc. 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 93,214 8,570,585 7,886,837 Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 51,056 7,558,198 9,036,912 Boeing Co./The 51,056 7,558,198 9,036,912 Total Industrials 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 4,401,432 3,789,062 Advanced Micro Devices, Inc. 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896	Corpay, Inc.	21,021	6,290,280	7,113,927
Total Financials 37,900,686 40,736,313 Health Care - 14.7% Avantor, Inc. 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 93,214 8,570,585 7,886,837 Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 30,094,777 27,575,093 Industrials - 9.0% 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 15,320,891 17,008,166 Technology - 29.3% 4401,432 3,789,062 3,689,428 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 30,396 14,296,289 19,979,963 0nto Innovation, Inc. 67,538 11,256,559 Total Technology 10,003 15,208,917 13,689,428 14,296,289 19,979,963 Onto Innovation, Inc. 67,538	First American Financial Corporation	137,108	8,793,804	8,561,024
Health Care - 14.7% Avantor, Inc. 242,475 Axsome Therapeutics, Inc. 93,214 8,570,585 7,886,837 Vaxcyte, Inc. 98,805 Zoetis, Inc. 98,805 7 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 Industrials - 9.0% 51,056 Boeing Co./The 51,056 Rockwell Automation, Inc. 27,892 Total Industrials 7,762,693 Total Industrials 15,320,891 Total Industrials 15,320,891 Total Industrials 15,320,891 Technology - 29.3% 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,266,559 10,997,963 Total Technology 49,982,085 55,110,897 <	Intercontinental Exchange, Inc.	78,518	10,852,190	11,699,967
Avantor, Inc. 242,475 5,812,801 5,108,948 Axsome Therapeutics, Inc. 93,214 8,570,585 7,886,837 Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Total Financials		37,900,686	40,736,313
Axsome Therapeutics, Inc. 93,214 8,570,585 7,886,837 Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 4401,432 3,789,062 Advanced Micro Devices, Inc. 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Health Care - 14.7%			
Vaxcyte, Inc. 98,805 9,179,936 8,088,177 Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 4,401,432 3,789,062 Advanced Micro Devices, Inc. 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Avantor, Inc.	242,475	5,812,801	5,108,948
Zoetis, Inc. 39,840 6,531,455 6,491,131 Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 51,056 7,558,198 9,036,912 Boeing Co./The 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897 <td>Axsome Therapeutics, Inc.</td> <td>93,214</td> <td>8,570,585</td> <td>7,886,837</td>	Axsome Therapeutics, Inc.	93,214	8,570,585	7,886,837
Total Health Care 30,094,777 27,575,093 Industrials - 9.0% 51,056 7,558,198 9,036,912 Boeing Co./The 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Vaxcyte, Inc.	98,805	9,179,936	8,088,177
Industrials - 9.0% Boeing Co./The 51,056 7,558,198 9,036,912 Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Zoetis, Inc.	39,840	6,531,455	6,491,131
Boeing Co./The Rockwell Automation, Inc. 51,056 7,558,198 9,036,912 Total Industrials 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Total Health Care		30,094,777	27,575,093
Rockwell Automation, Inc. 27,892 7,762,693 7,971,254 Total Industrials 15,320,891 17,008,166 Technology - 29.3% 31,369 4,401,432 3,789,062 Advanced Micro Devices, Inc. 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Industrials - 9.0%			
Total Industrials 15,320,891 17,008,166 Technology - 29.3% 31,369 4,401,432 3,789,062 Advanced Micro Devices, Inc. 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Boeing Co./The	51,056	7,558,198	9,036,912
Technology - 29.3% Advanced Micro Devices, Inc. 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Rockwell Automation, Inc.	27,892	7,762,693	7,971,254
Advanced Micro Devices, Inc. 31,369 4,401,432 3,789,062 Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Total Industrials		15,320,891	17,008,166
Coherent Corporation 67,517 4,266,689 6,395,885 DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Technology - 29.3%			
DigitalOcean Holdings, Inc. 401,803 15,208,917 13,689,428 Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Advanced Micro Devices, Inc.	31,369	4,401,432	3,789,062
Marvell Technology, Inc. 180,896 14,296,289 19,979,963 Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	Coherent Corporation		4,266,689	6,395,885
Onto Innovation, Inc. 67,538 11,808,758 11,256,559 Total Technology 49,982,085 55,110,897	DigitalOcean Holdings, Inc.	401,803	15,208,917	13,689,428
Total Technology 49,982,085 55,110,897	Marvell Technology, Inc.	180,896	14,296,289	19,979,963
	Onto Innovation, Inc.	67,538	11,808,758	11,256,559
Total Common Stocks 172,950,402 180,940,107			49,982,085	55,110,897
	Total Common Stocks		172,950,402	180,940,107

Lazard US Equity Concentrated CIT

Schedule of Investments (continued) December 31, 2024

	Principal Amount or Shares	Cost	Fair Value
Real Estate Investment Trusts - 3.7%			
Real Estate - 3.7%			
Crown Castle, Inc.	76,106	\$ 7,662,920	\$ 6,907,381
Total Real Estate		7,662,920	6,907,381
Total Real Estate Investment Trusts		 7,662,920	 6,907,381
Money Market Trusts - 0.2%			
NT Collective Government Short Term Investment Fund	314,279	 314,279	314,279
Total Money Market Trusts		314,279	314,279
Total Investments - 100.0%		\$ 180,927,601	188,161,767
Other Assets and Liabilities, Net - 0.0%			 31,903
Net Assets - 100.0%			\$ 188,193,670

The following is a summary of the fair value of the investments in the Fund based on the inputs used to value them as of December 31, 2024 (see Note 3 in Notes to the Financial Statements):

	Fair Value Measurements									
	Level 1		Level 2			Level 3		Investr Measu Net Asse	red at	Total
Common Stocks	\$ 180,940,107	\$		-	\$		-	\$	-	\$ 180,940,107
Real Estate Investment Trusts	6,907,381			-			-		-	6,907,381
Money Market Trusts	-			-			-		314,279	314,279
Total	\$ 187,847,488	\$		-	\$		-	\$	314,279	\$ 188,161,767

*Certain investments that are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Statement of Assets and Liabilities.

Concentration of Ownership: As of December 31, 2024, the Fund had two unitholders holding 10% or more of the outstanding units of the Fund, and aggregated to 99.0% of the Fund's total units outstanding.

Supplementary Information (Unaudited): Total investment purchases, sales proceeds, and realized gain for the year ended December 31, 2024, were:

	Purchases at Cost			Sales Proceeds	Realized Gain
Equity	\$	436,925,728	\$	546,774,436	\$ 62,758,108
Money Market		198,126,152		206,725,838	-
Total	\$	635,051,880	\$	753,500,274	\$ 62,758,108

Lazard US Equity Concentrated CIT

Statement of Assets and Liabilities December 31, 2024		
Assets Investments in securities, at fair value (cost \$180,927,601) Cash and cash equivalents Receivable for fund units sold Dividends receivable Total assets	\$ 188,161,767 110,681 362,486 11,937 188,646,871	
Liabilities Payable for fund units redeemed Accrued trustee and sub-advisor fees Accrued professional services and other operating expenses Total liabilities	 324,174 116,591 12,436 453,201	
Net Assets	\$ 188,193,670	
Statement of Operations For the year ended December 31, 2024		
Investment Income (Loss)		
Income Dividends Total income	\$ <u>3,466,684</u> 3,466,684	
Expenses Trustee and sub-advisor fees Professional services and other operating expenses Total expenses Net investment income	 797,915 35,308 833,223 2,633,461	
Realized and Unrealized Gain / Loss		
Net realized gain (loss) on: Investments Net realized gain Change in net unrealized gain / loss on:	 62,758,108 62,758,108	
Investments Change in net unrealized gain / loss Net realized and unrealized gain / loss	 (27,279,075) (27,279,075) 35,479,033	
Increase in net assets from operations	\$ 38,112,494	

The accompanying notes are an integral part of these financial statements.

Lazard US Equity Concentrated CIT

Statement of Changes in Net Assets For the year ended December 31, 2024

Increase (Decrease) in Net Assets Operations		
Net investment income	\$	2,633,461
Net realized gain	Ť	62,758,108
Change in net unrealized gain / loss		(27,279,075)
Increase in net assets from operations		38,112,494
Unit transactions		
Proceeds from units issued		
Class 0		393,911
Class 0C [^]		61,418
Class F		47,131,918
Class LZ		1,694,242
Total proceeds from units issued		49,281,489
Value of units redeemed		
Class 0		(372,758)
Class 0C [^]		(2,141,628)
Class F		(156,520,445)
Class LZ		(11,377,784)
Total value of units redeemed		(170,412,615)
Decrease in net assets resulting from unit transactions		(121,131,126)
Decrease in net assets		(83,018,632)
Net assets, beginning of year		271,212,302
Net assets, end of year	\$	188,193,670

^ All Class 0C units were redeemed on 5/23/2024. The fee class remains available for sale.

The accompanying notes are an integral part of these financial statements.

Lazard US Equity Concentrated CIT

Financial Highlights For the year ended December 31, 2024

Per Unit Operating Performance	Class 0		Class 0C		lass OC C		C	Class LZ
Net asset value, beginning of year	\$	17.4100	\$	16.5600	\$	16.6300	\$	16.9500
Investment operations:								
Net investment income ⁽¹⁾		0.2375		0.0473		0.1647		0.2248
Net realized and unrealized gain / loss ⁽¹⁾		1.8010		0.0879		1.7214		1.7553
Total from investment operations		2.0385		0.1352		1.8861		1.9801
Net asset value, end of year	\$	19.4485	\$	16.6952 [«]	\$	18.5161	\$	18.9301
Total Return		11.71%		0.82%^		11.34%		11.68%
Supplemental Data								
Ratio to average net assets:								
Expenses		0.01%		0.61%#		0.37%		0.05%
Net investment income		1.28%		0.73%#		0.94%		1.25%
Unit Activity								
Units, beginning of year		94,994		124,514	1	3,334,384		2,698,868
Issued		22,495		3,727		2,759,260		95,530
Redeemed		(20,402)		(128,241)	((8,246,788)		(627,891)
Units, end of year		97,087		-		7,846,856		2,166,507

⁽¹⁾ Based on average units outstanding.

« All Class 0C units were redeemed on 5/23/2024. The fee class remains available for sale. The net asset value is as of the redemption date of 5/23/2024.

^ Not annualized for periods less than one year.

Annualized except audit expense.

Lazard US Equity Concentrated CIT

Notes to the Financial Statements

December 31, 2024

Note 1 – Organization

Great Gray Collective Investment Trust (the "Trust") is intended to constitute an exempt trust under Section 501(a) of the Internal Revenue Code of 1986, as amended (the "Code"), and a group trust within the meaning of Rev. Rul. 81-100, as amended. The Trust is exempt from registration under the Investment Company Act of 1940, as amended, and the Securities Act of 1933, as amended. Great Gray Trust Company, LLC (the "Trustee") serves as the Trustee of the Trust.

The Trustee is responsible for maintaining and administering the Trust and the Lazard US Equity Concentrated CIT (the "Fund") and also serves as the investment manager to the Fund. The Northern Trust Company provides custody, transfer agency, and accounting services for the Fund.

The Trustee is ultimately controlled by Madison Dearborn Partners, LLC ("MDP"), a registered investment adviser and private equity firm based in Chicago, IL. MDP and its controlled subsidiaries are the general partners to the investment funds that own substantially all of the Trustee through intermediate holding companies.

The purpose of the Trust is to allow collective investments by plan sponsors of retirement plans which qualify for exemption from federal income taxation pursuant to Section 501(a) of the Code, by reason of qualifying under Section 401(a) of the Code; tax-exempt governmental plans described in Section 401(a)(24) of the Code; eligible deferred compensation plans under Section 457(b) of the Code established by a government employer; group trusts or separate accounts consisting solely of assets of the foregoing; and other investors eligible for participation in the Trust. The Trust consists of separate funds with differing investment objectives, which are available for investment by participating plans. An eligible plan may join the Trust, subject to the Trustee's acceptance, and become a participating plan by executing participation documents specified by the Trustee. Not all funds within the Trust are presented herein. The Trustee has claimed an exclusion from the definition of commodity pool operator ("CPO") under the Commodity Exchange Act and the rules of the Commodity Futures Trading Commission ("CFTC") with respect to the Fund, and is therefore not subject to CFTC registration or regulation as a CPO with respect to the Fund.

The investment objective of the Fund is to provide long-term capital appreciation by investing in a concentrated portfolio of investments, primarily in equity securities issued by U.S. companies of any market capitalization. The Trustee has engaged Lazard Asset Management LLC (the "Sub-Advisor") to provide investment advice in connection with the investment of the Fund's assets. The Trustee maintains ultimate fiduciary authority over the management of and investments made in the Fund. The Sub-Advisor is engaged pursuant to a sub-advisor agreement.

Note 2 – Significant Accounting Policies

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Fund is an investment company and follows the accounting and reporting guidance in Financial Accounting Standards Board Accounting Standards Codification Topic No. 946.

Net Asset Value ("NAV") – Units of each fee class of the Fund are valued each day on which the New York Stock Exchange ("NYSE") is open for trading in accordance with the valuation procedures established by the Trustee. The NAV per unit is calculated as of the close of trading on the NYSE (generally, 4:00 p.m. U.S. Eastern time). The NAV per

Lazard US Equity Concentrated CIT

Notes to the Financial Statements (continued)

December 31, 2024

unit is computed by dividing the total fair value of the assets of the Fund, less its liabilities, by the total number of units outstanding at the time of such computation. Investment income earned is reinvested in the Fund and included in the determination of unit values.

Fund Unit Transactions – The Fund sells new units and repurchases outstanding units on a daily basis. Unit purchases and redemptions are transacted at the NAV per fee class of the Fund determined as of the close of business each day. A summary of the Fund unit activity for the Fund is included with its Financial Highlights.

Investment Valuation – Investments are valued at their current fair value determined as follows:

Money Market Trusts – Investments in money market trusts are valued using the net asset value per share (or its equivalent) as a practical expedient in accordance with the specialized accounting guidance for investment companies.

Securities – Securities, other than bonds, listed on a securities exchange, market or automated quotation system for which quotations are readily available are valued at the closing price on the primary exchange or market on which they are traded on the day of valuation or, if there is no such reported sale on the valuation date, at the most recent bid quotation on the principal exchange. If a market price is not readily available or if such price is deemed unreliable, it will be valued at fair value in accordance with valuation procedures established by the Trustee. The Trustee's determination of fair value involves consideration of a number of subjective factors, and therefore, no single standard for determining fair value will apply.

When the valuation methods described above are not reflective of fair value, investments are valued at fair value following procedures and/or guidelines determined by or under the direction of the valuation committee established by the Trustee. In light of the judgment involved in fair value decisions, there can be no assurance that a fair value assigned to a particular investment is accurate.

Cash and Cash Equivalents – The Fund considers all highly liquid instruments with original maturities of three months or less at the acquisition date to be cash equivalents.

Investment Transactions and Investment Income – The Fund records security transactions on a trade date basis. Dividend income is recorded on the ex-dividend date. Net realized gains and losses on investments are determined by the first-in, first-out method. Interest income and expenses are recorded daily on the accrual basis.

Fee Classes and Allocations – The Fund offers multiple fee classes. Not all fee classes are available for investment by all plans. Each class is allocated expenses on the basis of expense loads assigned to that class. Income, expenses (other than expenses attributable to a specific class), and realized and unrealized gains or losses on investments are allocated to each fee class based on the units outstanding for the fee class in proportion to the total outstanding units.

Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Lazard US Equity Concentrated CIT

Notes to the Financial Statements (continued)

December 31, 2024

Guarantees and Indemnifications – Under the Fund's organizational documents, each trustee, officer, employee and agent of the Trust is indemnified, to the extent permitted by law, against certain liabilities that may arise in the performance of their duties to the Fund.

Income Tax Status – The Trust has received a determination from the Internal Revenue Service that the Trust is exempt from federal income taxation under Section 501(a) of the Code. Accordingly, no federal income tax provision is required.

Subsequent Events – The Trustee has evaluated the effect of subsequent events on the Fund's financial statements through April 30, 2025, which is the date the financial statements were available to be issued, and has determined that there are no material subsequent events that would require disclosure or adjustment in the Fund's financial statements through this date.

Note 3 - Fair Value Measurements

Fair value is defined as the price a fund would receive to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date.

Various inputs are used in determining the fair value of the Fund's investments. The Trustee has performed an analysis of the significance and character of these inputs to the fair value determination. These inputs are summarized in the three broad levels listed below:

- Level 1 Quoted prices in active markets for identical investments.
- Level 2 Other significant observable inputs (including quoted prices for similar investments, interest rates, credit risk, and others).
- Level 3 Significant unobservable inputs (including the Trustee's own assumptions in determining the fair value of investments).

The inputs or methodologies used for valuing investments are not necessarily an indication of the risk associated with investing in those investments. The aggregate fair value of the investments in the Fund, by input level used as of December 31, 2024, is included following the Fund's Schedule of Investments.

Lazard US Equity Concentrated CIT

Notes to the Financial Statements (continued)

December 31, 2024

Note 4 - Fees and Expenses

Trustee and Sub-Advisor Fees

Annualized asset-based fees are based upon the net assets as determined at the end of each preceding business day as set forth in the table below (in basis points). Except as otherwise noted, all asset-based fees are paid from the assets of the Fund.

Fee Class	Trustee Fee	Sub-Advisor Fee ⁽¹⁾
Class 0	0	0
Class 0C	0	60
Class F	4	50 for first \$50 million of assets 40 for next \$150 million of assets 35 for assets over \$200 million
Class LZ	4	0

⁽¹⁾ Effective as of July 1, 2024, until March 31, 2025, the Sub-Advisor has agreed to waive a portion of its fee so that Class F Units shall bear the Sub-Advisory Fee at the annual rate of 0.25% on the first \$50 million, 0.20% on the next \$150 million, and 0.175% on the balance of the Sub-Advised Fund's average daily net assets attributable to such Class. The Sub-Advisor Fee will be reduced accordingly during this waiver period.

Trustee Fee – The Trustee receives an annualized fee for supervising the overall investment and management of the Fund and for the trustee, administrative and management services provided to the Fund. Trustee fees are based upon the average daily value of the Fund and are accrued daily, paid quarterly in arrears and charged against the assets invested in the Fund.

Sub-Advisor Fee – The Sub-Advisor is compensated for its investment advisory services provided to the Fund. These annualized fees are based upon the average daily value of the Fund and are accrued daily, paid quarterly in arrears and charged against the assets invested in the Fund.

Operating Expenses – In addition to the fees described above, the Fund bears expenses related to its operations, including, but not limited to, audit, custody, tax and legal services. Transaction fees and expenses incurred in connection with the investment and reinvestment of Fund assets, including, without limitation, brokerage commission and other expenses, are also charged against the Fund.

When assets of the Fund are invested in other investment vehicles, such as other Collective Funds or Exchange-Traded Funds, those investment vehicles will incur fees and expenses, which will be reflected in the performance results and value of the Fund's investment in such investment vehicle.

Lazard US Equity Concentrated CIT

Notes to the Financial Statements (continued)

December 31, 2024

Note 5 – Related Party Transactions

The Trustee is a Nevada-chartered non-depository trust company that provides trust and custodial services for tax-advantaged retirement plans as well as trust and investment services to business pension and retirement plans. The Trustee is responsible for managing the Trust's investment and business affairs.

Note 6 - Risks Associated with Investing in the Fund

In the normal course of business, the Fund trades financial instruments and enters into financial transactions where risk of potential loss exists due to changes in the fair value of the investments.

The following are the principal risks of the Fund and are described in the Additional Fund Information and Principal Risk Definitions (www.greatgray.com/principalriskdefinitions):

Active Management, Equity Securities, Foreign Securities, Issuer, Large Cap, Market/Market Volatility, Mid-Cap, Other, Small Cap.